SIASUN(SZ:300024) 3 6 Ke·2025-07-20 10:02Core Insights - Wandercraft, a French exoskeleton robotics company, completed a $75 million Series D funding round to advance the commercialization of its core product, the Eve system, and to support international deployment of Atalante X and validation of Calvin-40 production [1][15]. Funding and Financial Overview - Since its establishment in 2012, Wandercraft has raised a total of $137 million through multiple funding rounds, with the latest Series D round contributing $75 million [1]. - The funding history includes: - €4 million in Series A (July 2015) for initial R&D and product prototype development - €17.8 million in Series B (October 2017) for expanding R&D and clinical validation - €45 million in Series C (January 2022) for accelerating market promotion and international certification of Atalante X [1]. Product Development and Market Strategy - Wandercraft has developed three exoskeleton robots targeting medical, consumer, and industrial markets: Atalante X, Eve, and Calvin-40 [6]. - Atalante X is designed for rehabilitation of patients with mobility impairments, featuring a self-balancing system and 12 degrees of freedom for natural gait simulation [9][10]. - Eve is a home care robot aimed at post-discharge rehabilitation, currently in clinical trials with plans for a 2026 launch in the U.S. [13]. - Calvin-40 is an industrial humanoid robot designed for high-risk labor tasks, with initial deployment planned for late 2025 [14]. Industry Trends and Market Potential - The global rehabilitation market has a significant gap, with approximately 20 million spinal cord injury patients needing effective rehabilitation devices [5]. - The Chinese exoskeleton robot market is projected to reach ¥4.2 billion by 2025, with a compound annual growth rate of about 50% from 2023 to 2028 [16]. - The demand for rehabilitation solutions is driven by a high incidence of stroke and spinal cord injuries in China, with over 28 million stroke patients and 3.74 million spinal cord injury patients reported [18]. Collaborations and Innovations - The partnership with Renault marks a shift in investment strategy, providing not only financial backing but also manufacturing resources for the Calvin-40 robot [15]. - Collaboration with NVIDIA aims to enhance the technological capabilities of Wandercraft's robots through AI training and simulation [15]. Regulatory and Policy Environment - Recent policies in China support the development of exoskeleton robots as high-end medical equipment, facilitating industry growth and standardization [18]. - The competitive landscape has intensified with domestic companies innovating in niche areas, such as rehabilitation solutions for specific patient demographics [18].